85
Participants
Start Date
May 31, 2009
Primary Completion Date
December 31, 2009
Study Completion Date
January 31, 2015
COBI
Cobicistat (COBI) 150 mg tablet administered orally once daily
RTV
Ritonavir (RTV) 100 mg soft gelatin capsule administered orally once daily
ATV
Atazanavir (ATV) 300 mg capsule administered orally once daily
FTC/TDF
Emtricitabine (FTC) 200 mg/tenofovir disoproxil fumarate (TDF) 300 mg fixed-dose combination tablet administered orally once daily
COBI placebo
Placebo to match COBI administered orally once daily
RTV placebo
Placebo to match RTV administered orally once daily
Dupont Circle Physicians Group, Washington D.C.
Whitman Walker Clinic, Washington D.C.
Capital Medical Associates PC, Washington D.C.
Chase Brexton Health Services, Inc., Baltimore
Rosedale Infectious Diseases, Huntersville
Infectious Disease Specialists of Atlanta (IDSA), Decatur
AIDS Research Consortium of Atlanta, Atlanta
ValuehealthMD, LLC, Orlando
Wohlfeiler, Piperato and Associates, LLC, Miami Beach
Gary Richmond, MD, PA, Inc., Fort Lauderdale
St. Joseph's Comprehensive Research Institute, Tampa
Be Well Medical Center, Berkley
Northstar Medical Center, Chicago
Central West Healthcare, St Louis
Southampton Healthcare, Inc., St Louis
Health for Life Clinic, PLLC, Little Rock
Nicholaos Bellos, MD, PA, Dallas
AIDS Arms/ Peabody Health Center, Dallas
Gordon E. Crofoot, MD, PA, Houston
Therapeutic Concepts, P.A., Houston
Denver Infectious Disease Consultants, PLLC, Denver
Southwest Center for HIV/AIDS, Phoenix
Southwest C.A.R.E. Center, Santa Fe
Peter J. Ruane, MD, Inc., Los Angeles
AIDS Healthcare Foundation-Research Center, Beverly Hills
The Living Hope Foundation, Long Beach
David J. Shamblaw, MD Inc., San Diego
Orange Coast Medical Group, Newport Beach
Metropolis Medical, San Francisco
TribalMed, Seattle
Saint Michael's Medical Center, Newark
Lead Sponsor
Gilead Sciences
INDUSTRY